Conditions: Non-small Cell Lung Cancer
Keywords: cetuximab tyrosine kinase inhibitor
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 56
Healthy volunteers: no

Brief summary:
The purpose of this research study is to find out how well cetuximab works in treating NSCLC in patients who have been previously treated with a class of drug called tyrosine kinase inhibitor (TKI). Cetuximab is a protein that is designed to block a substance in cancer cells called "epidermal growth factor receptor" or EGFR. EGFR helps cancer cells grow.

Detailed description:
* Participants on this study will receive cetuximab by infusion intravenously once per week and may continue to receive weekly cetuximab infusions until their disease progresses or they experience unacceptable side effects.
* The following will be performed every 4 weeks while they are receiving study treatments: Physical examination; performance status; and blood work. A CT scan of the chest and upper abdomen will be performed every 8 weeks.

Arms:
arm 1: 400mg/m2 IV x 1 and then 250mg/m2 IV weekly

Interventions: intervention 1: Cetuximab
Intervention descriptions: intervention 1: Given intravenously once per week.

Protocol document: